| scholarly article | Q13442814 |
| P50 | author | Steven E Kern | Q98164169 |
| P2093 | author name string | Pravin R. Jadhav | |
| P2860 | cites work | Mechanistic basis of using body size and maturation to predict clearance in humans | Q37404427 |
| Pediatric antihypertensive trial failures: analysis of end points and dose range | Q37436147 | ||
| Drug therapy in pediatrics: a developing field | Q37488352 | ||
| Carvedilol for children and adolescents with heart failure: a randomized controlled trial. | Q38395213 | ||
| Candesartan cilexetil effectively reduces blood pressure in hypertensive children | Q42663516 | ||
| Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. | Q44012404 | ||
| The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design | Q44135194 | ||
| Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study. | Q45927030 | ||
| Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method. | Q46156878 | ||
| Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years | Q46193460 | ||
| Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. | Q47569147 | ||
| The importance of randomized controlled trials in pediatric cardiology | Q81234779 | ||
| Proposals for model-based paediatric medicinal development within the current European Union regulatory framework | Q28749999 | ||
| Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants | Q30435365 | ||
| Population pharmacokinetics of fluconazole in young infants | Q30439710 | ||
| Pharmacokinetics And Pharmacodynamics Of Fenoldopam Mesylate For Blood Pressure Control In Pediatric Patients | Q33374155 | ||
| The FDA critical path initiative and its influence on new drug development. | Q34734622 | ||
| Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. | Q36536474 | ||
| Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety | Q36565063 | ||
| Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006. | Q36720907 | ||
| Improving pediatric dosing through pediatric initiatives: what we have learned | Q37098241 | ||
| Quantitative disease, drug, and trial models | Q37292641 | ||
| Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents | Q37379360 | ||
| P433 | issue | 9 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | modelling biological systems | Q4299308 |
| P304 | page(s) | 121S-129S | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | The need for modeling and simulation to design clinical investigations in children | |
| The Need for Modeling and Simulation to Design Clinical Investigations in Children | |||
| P478 | volume | 50 |
| Q34554486 | Bridging the gap: a review of dose investigations in paediatric investigation plans |
| Q37666706 | Drug Development for Pediatric Populations: Regulatory Aspects |
| Q36322918 | Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children |
| Q33658786 | Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review |
| Q38016332 | Physiologically based pharmacokinetic (PBPK) modeling in children |
| Q41975490 | Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug |
Search more.